Clinical Updates – November 24, 2020
Cases, hospitalizations and deaths are reaching critical levels across the country. This Clinical Update is a reminder of the resources that have remained available to you and your teams since the early months of the pandemic.
Accessing PPE and Mask Utilization
- The health and safety of our teams are of the utmost importance. If your hospitals cannot provide adequate PPE, please reach out immediately to your PPE captain or to Procurement at PPENeeds@EnvisionHealth.com.
- ACP Study: Use of N95 Surgical & Cloth Masks to Prevent COVID-19 in Health Care and Community Settings-Living Practice Points
- All healthcare personnel in close contact with patients suspected or known to have COVID-19 should use N95 respirators in healthcare settings to reduce the risk for acquiring SARS-CoV-2 infection.
- All patients with suspected or known COVID-19 should wear surgical masks in healthcare settings.
- All healthcare personnel, patients and visitors who are not in close contact with patients with suspected or known COVID-19 should use surgical masks in healthcare settings to reduce the risk for transmission of SARS-CoV-2 infection.
- Healthcare personnel should not use cloth masks in healthcare settings to reduce the risk for transmission of SARS-CoV-2 infection. Cloth masks are not considered PPE in healthcare settings, given the lack of evidence of their effectiveness against transmission of SARS-CoV-2 virus.
- Georgia Tech has developed a risk assessment tool for predicting COVID-19 infections within groups based on location and size of an event.
Updates on the Pfizer, Moderna and AstraZeneca Vaccines
- Pfizer announced a COVID-19 vaccine that is 90 percent effective according to an interim analysis by an independent data monitoring committee. You can view Pfizer’s study design here.
- Despite the positive news, widespread distribution of the vaccine is not imminent.
- Moderna has also released preliminary findings for its COVID-19 vaccine.
- Early Phase 3 reports indicate 95 percent efficacy based on an analysis of 95 cases among 30,000 participants.
- Moderna hopes to have 20 million doses available in the U.S. and more than a billion doses available globally by next year if the vaccine is awarded FDA approval.
- AstraZeneca's vaccine is up to 90 percent effective and easily transportable, the company says.
- The University of Oxford and AstraZeneca developed the vaccine and released early Phase 3 findings on Monday, November 23.
- Efficacy is based on administering a half-dose and then full booster dose a month later.
- The vaccines appear to be more affordable and easier to store and transport than alternatives.
Clinician Deployments to Areas with COVID Surges
- Interested clinicians can sign up to be a part of the Envision Disaster Assistance Response Team (DART) by completing the DART Volunteer Questionnaire.
- Hospitals, governments and state preparedness programs requesting disaster assistance or COVID-19 surge coverage can contact Roylene Rhodes at Roylene.Rhodes@EnvisionHealth.com
- Envision facilities and site clinical leaders requesting disaster assistance or surge coverage can work with their SVP/DOO to request ENVOY Traveler and Contingent Locum coverage directly through our ENVOY Operations team.